Nicolas Bonnet

📃Scientific paper: Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives Abstract: Background Seasonal influenza epidemics have a substantial public health and economic burden, which can be alleviated through vaccination. The World Health Organization (WHO) recommends a 75% vaccination coverage rate (VCR) in: older adults (aged ≥ 65 years), individuals with chronic conditions, pregnant women, children aged 6–24 months and healthcare workers. However, no European country achieves this target in all risk groups. In this study, potential public health and economic benefits achieved by reaching 75% influenza VCR was estimated in risk groups across four European countries: France, Italy, Spain, and the UK. Methods A static epidemiological model was used to estimate the averted public health and economic burden of increasing the 2021/2022 season VCR to 75%, using the efficacy data of standard-dose quadrivalent influenza vaccine. For each country and risk group, the most recent data on population size, VCR, pre-pandemic influenza epidemiology, direct medical costs and absenteeism were identified through a systematic literature review, supplemented by manual searching. Outcomes were: averted influenza cases, general practitioner (GP) visits, hospitalisations, case fatalities, number of days of work lost, direct medical costs and absenteeism-related costs. Results As of the 2021/2022 season, the UK achieved the highest weighted VCR across risk groups (65%), followed by Spain (47%), France (44%) and Italy (44%). Based on modelling, the 2021/2022 VCR prevent... Continued on ES/IODE ➡️ https://etcse.fr/97kG ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives Abstract: Background Seasonal influenza epidemics have a substantial public health and economic burden, which can be alleviated through vaccination. The World Health Organization (WHO) recommends a 75% vaccination coverage rate (VCR) in: older adults (aged ≥ 65 years), individuals with chronic conditions, pregnant women, children aged 6–24 months and healthcare workers. However, no European country achieves this target in all risk groups. In this study, potential public health and economic benefits achieved by reaching 75% influenza VCR was estimated in risk groups across four European countries: France, Italy, Spain, and the UK. Methods A static epidemiological model was used to estimate the averted public health and economic burden of increasing the 2021/2022 season VCR to 75%, using the efficacy data of standard-dose quadrivalent influenza vaccine. For each country and risk group, the most recent data on population size, VCR, pre-pandemic influenza epidemiology, direct medical costs and absenteeism were identified through a systematic literature review, supplemented by manual searching. Outcomes were: averted influenza cases, general practitioner (GP) visits, hospitalisations, case fatalities, number of days of work lost, direct medical costs and absenteeism-related costs. Results As of the 2021/2022 season, the UK achieved the highest weighted VCR across risk groups (65%), followed by Spain (47%), France (44%) and Italy (44%). Based on modelling, the 2021/2022 VCR prevent... Continued on ES/IODE ➡️ https://etcse.fr/97kG ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Source: (Die Anaesthesiologie) Intensive care medicine has high resource consumption impacting environmental sustainability. Key issues include ecotoxicity from drugs, excessive use of disposables, and significant energy use. Solutions involve reducing waste, recycling, and measuring consumption, potentially aided by AI. Sustainability training and research should prioritize ecological aspects alongside economic ones. Misuse and overuse of intensive care increase costs and ecological footprints. A collaborative Green Team approach is essential for promoting sustainability in intensive care units.

Editoriale da la Revue Prescrire International "A tale of risk Each drug has its own story. Some are fine tales of discovery: the discovery of a rare or not so rare disease, its serious or not so serious consequences, its natural course and causes, and then an effective treatment. In the best stories, the treatment benefits numerous patients for a very long time, its risks are considered acceptable, and the price society pays for it is fair. Often though, it’s an everyday story of markets, target populations, territories, influence, and so on, hard fought for and won. In short, a story that revolves around money… And for some drugs, the story ends. Perhaps the drug was withdrawn from the market, pulled discreetly and silently from the shelves, even though such decisions often indicate that the drug was more dangerous than beneficial, or that it was no longer sufficiently profitable. Or it might go out with more of a bang, with those who promoted the drug facing justice for the public health disaster it caused, and those responsible having to explain themselves in court. Sometimes the end was premeditated, to insidiously orchestrate the imminent arrival of a new drug, to fabricate a need or manufacture a shortage. What do these stories have in common? They all revolve around the same main characters: patients. It is patients who live with the disease and all of its consequences. It is patients who form groups to have their voices heard and to advance research. It is volunteers and patients who contribute to research by participating in preliminary studies, then in clinical trials, their bodies used to experiment with new substances, with no certainty whatsoever over the nature of the effects these substances will produce. It is patients who describe, or sometimes report, unexpected or serious adverse effects. Effects that may have severe sequelae, even when the drug responsible has been withdrawn, or even end in tragedy for some patients and the family and friends they leave behind. Whatever the drug, its story and how it is told, it is always patients who are exposed to the risks of diseases for which no acceptable treatment exists. But it is also patients who are exposed to the risks of inadequately evaluated drugs. Prescrire"

📃Scientific paper: The use of patient‐reported outcome measures by healthcare professionals in specialized asthma management centers in French‐speaking Belgium: A mixed‐methods study Abstract: INTRODUCTION: Recently, the literature has promoted the use of patient‐reported outcome measures (PROMs) in clinical practice as a means to foster patient engagement. However, conditions necessary to support the use of PROMs to encourage asthma patient engagement are not clearly defined. Therefore, we sought (1) to explore the current and ideal use of PROMs by healthcare professionals (HP) in specialized asthma management centers in French‐speaking Belgium and (2) to understand under which conditions the use of PROMs contributes to patient engagement. METHODS: We undertook a mixed‐methods study with both anonymous online survey and in‐person qualitative semi‐structured interviews conducted with HPs to understand their perspectives on the routine use of PROMs. HPs were recruited from 16 asthma centers (French‐speaking Belgium) identified via the Belgian Respiratory Society. RESULTS: Of the 170 HPs identified from the 16 participating centers, 51 (30%) responded to the survey (n = 51) and 11 completed semi‐structured interviews. 53% (27/51) of the surveyed HPs reported using PROMs primarily for asthma monitoring and clinical research while all reported that PROMs should primarily be used in practice to facilitate communication with the patient and to address neglected aspects of the care relationship such as the psychosocial aspects of the disease. The qualitative interviews revealed avenues for moving from a medical‐centered and utilitarian use of PROMs to a use servi... Continued on ES/IODE ➡️ https://etcse.fr/061j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: The use of patient‐reported outcome measures by healthcare professionals in specialized asthma management centers in French‐speaking Belgium: A mixed‐methods study Abstract: INTRODUCTION: Recently, the literature has promoted the use of patient‐reported outcome measures (PROMs) in clinical practice as a means to foster patient engagement. However, conditions necessary to support the use of PROMs to encourage asthma patient engagement are not clearly defined. Therefore, we sought (1) to explore the current and ideal use of PROMs by healthcare professionals (HP) in specialized asthma management centers in French‐speaking Belgium and (2) to understand under which conditions the use of PROMs contributes to patient engagement. METHODS: We undertook a mixed‐methods study with both anonymous online survey and in‐person qualitative semi‐structured interviews conducted with HPs to understand their perspectives on the routine use of PROMs. HPs were recruited from 16 asthma centers (French‐speaking Belgium) identified via the Belgian Respiratory Society. RESULTS: Of the 170 HPs identified from the 16 participating centers, 51 (30%) responded to the survey (n = 51) and 11 completed semi‐structured interviews. 53% (27/51) of the surveyed HPs reported using PROMs primarily for asthma monitoring and clinical research while all reported that PROMs should primarily be used in practice to facilitate communication with the patient and to address neglected aspects of the care relationship such as the psychosocial aspects of the disease. The qualitative interviews revealed avenues for moving from a medical‐centered and utilitarian use of PROMs to a use servi... Continued on ES/IODE ➡️ https://etcse.fr/061j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: The use of patient‐reported outcome measures by healthcare professionals in specialized asthma management centers in French‐speaking Belgium: A mixed‐methods study Abstract: INTRODUCTION: Recently, the literature has promoted the use of patient‐reported outcome measures (PROMs) in clinical practice as a means to foster patient engagement. However, conditions necessary to support the use of PROMs to encourage asthma patient engagement are not clearly defined. Therefore, we sought (1) to explore the current and ideal use of PROMs by healthcare professionals (HP) in specialized asthma management centers in French‐speaking Belgium and (2) to understand under which conditions the use of PROMs contributes to patient engagement. METHODS: We undertook a mixed‐methods study with both anonymous online survey and in‐person qualitative semi‐structured interviews conducted with HPs to understand their perspectives on the routine use of PROMs. HPs were recruited from 16 asthma centers (French‐speaking Belgium) identified via the Belgian Respiratory Society. RESULTS: Of the 170 HPs identified from the 16 participating centers, 51 (30%) responded to the survey (n = 51) and 11 completed semi‐structured interviews. 53% (27/51) of the surveyed HPs reported using PROMs primarily for asthma monitoring and clinical research while all reported that PROMs should primarily be used in practice to facilitate communication with the patient and to address neglected aspects of the care relationship such as the psychosocial aspects of the disease. The qualitative interviews revealed avenues for moving from a medical‐centered and utilitarian use of PROMs to a use servi... Continued on ES/IODE ➡️ https://etcse.fr/061j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: The use of patient‐reported outcome measures by healthcare professionals in specialized asthma management centers in French‐speaking Belgium: A mixed‐methods study Abstract: INTRODUCTION: Recently, the literature has promoted the use of patient‐reported outcome measures (PROMs) in clinical practice as a means to foster patient engagement. However, conditions necessary to support the use of PROMs to encourage asthma patient engagement are not clearly defined. Therefore, we sought (1) to explore the current and ideal use of PROMs by healthcare professionals (HP) in specialized asthma management centers in French‐speaking Belgium and (2) to understand under which conditions the use of PROMs contributes to patient engagement. METHODS: We undertook a mixed‐methods study with both anonymous online survey and in‐person qualitative semi‐structured interviews conducted with HPs to understand their perspectives on the routine use of PROMs. HPs were recruited from 16 asthma centers (French‐speaking Belgium) identified via the Belgian Respiratory Society. RESULTS: Of the 170 HPs identified from the 16 participating centers, 51 (30%) responded to the survey (n = 51) and 11 completed semi‐structured interviews. 53% (27/51) of the surveyed HPs reported using PROMs primarily for asthma monitoring and clinical research while all reported that PROMs should primarily be used in practice to facilitate communication with the patient and to address neglected aspects of the care relationship such as the psychosocial aspects of the disease. The qualitative interviews revealed avenues for moving from a medical‐centered and utilitarian use of PROMs to a use servi... Continued on ES/IODE ➡️ https://etcse.fr/061j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Comorbidities and drug management of parkinsonian patients : a pharmacoepidemiological and pharmacovigilance study;Comorbidités et prise en charge médicamenteuse des patients parkinsoniens : approche en pharmaco-épidémiologie et en pharmacovigilance Abstract: Idiopathic Parkinson's disease is the second most common neurodegenerative disease in France and its prevalence is expected to increase in the coming years. Currently, there is no curative drug and patient management is mainly based on symptomatic drugs. This thesis work was based on three hypotheses concerning the mechanism of disease appearance or progression : the involvement of the beta-adrenergic system in the occurrence of Parkinson's disease through the modulation of alpha-synuclein gene, the link between drug- induced Parkinsonism and Parkinson's disease, and finally, the influence of diabetes mellitus comorbidity on Parkinson's disease progression. To confirm these hypotheses, we used a population-based approach based on the National Health Data System (SNDS) and the WHO Pharmacovigilance Database (Vigibase®. In a nested case-control study from the SNDS, we failed to find any significant association between exposure to beta-adrenoceptor antagonists and Parkinson's disease occurrence but the effect of beta-adrenoceptor agonist exposure could vary according to the presence of diabetic comorbidity. The risk would increase in diabetics and inversely decrease in non-diabetics. In our work on drug-induced parkinsonism, the risk of reporting parkinsonism was higher in Europe compared to all other continents and lower in America and Asia, according to Vigibase®. These variations in geographical distribution could be related to different prescribing habits between co... Continued on ES/IODE ➡️ https://etcse.fr/2cX ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Comorbidities and drug management of parkinsonian patients : a pharmacoepidemiological and pharmacovigilance study;Comorbidités et prise en charge médicamenteuse des patients parkinsoniens : approche en pharmaco-épidémiologie et en pharmacovigilance Abstract: Idiopathic Parkinson's disease is the second most common neurodegenerative disease in France and its prevalence is expected to increase in the coming years. Currently, there is no curative drug and patient management is mainly based on symptomatic drugs. This thesis work was based on three hypotheses concerning the mechanism of disease appearance or progression : the involvement of the beta-adrenergic system in the occurrence of Parkinson's disease through the modulation of alpha-synuclein gene, the link between drug- induced Parkinsonism and Parkinson's disease, and finally, the influence of diabetes mellitus comorbidity on Parkinson's disease progression. To confirm these hypotheses, we used a population-based approach based on the National Health Data System (SNDS) and the WHO Pharmacovigilance Database (Vigibase®. In a nested case-control study from the SNDS, we failed to find any significant association between exposure to beta-adrenoceptor antagonists and Parkinson's disease occurrence but the effect of beta-adrenoceptor agonist exposure could vary according to the presence of diabetic comorbidity. The risk would increase in diabetics and inversely decrease in non-diabetics. In our work on drug-induced parkinsonism, the risk of reporting parkinsonism was higher in Europe compared to all other continents and lower in America and Asia, according to Vigibase®. These variations in geographical distribution could be related to different prescribing habits between co... Continued on ES/IODE ➡️ https://etcse.fr/2cX ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Comorbidities and drug management of parkinsonian patients : a pharmacoepidemiological and pharmacovigilance study;Comorbidités et prise en charge médicamenteuse des patients parkinsoniens : approche en pharmaco-épidémiologie et en pharmacovigilance Abstract: Idiopathic Parkinson's disease is the second most common neurodegenerative disease in France and its prevalence is expected to increase in the coming years. Currently, there is no curative drug and patient management is mainly based on symptomatic drugs. This thesis work was based on three hypotheses concerning the mechanism of disease appearance or progression : the involvement of the beta-adrenergic system in the occurrence of Parkinson's disease through the modulation of alpha-synuclein gene, the link between drug- induced Parkinsonism and Parkinson's disease, and finally, the influence of diabetes mellitus comorbidity on Parkinson's disease progression. To confirm these hypotheses, we used a population-based approach based on the National Health Data System (SNDS) and the WHO Pharmacovigilance Database (Vigibase®. In a nested case-control study from the SNDS, we failed to find any significant association between exposure to beta-adrenoceptor antagonists and Parkinson's disease occurrence but the effect of beta-adrenoceptor agonist exposure could vary according to the presence of diabetic comorbidity. The risk would increase in diabetics and inversely decrease in non-diabetics. In our work on drug-induced parkinsonism, the risk of reporting parkinsonism was higher in Europe compared to all other continents and lower in America and Asia, according to Vigibase®. These variations in geographical distribution could be related to different prescribing habits between co... Continued on ES/IODE ➡️ https://etcse.fr/2cX ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.